Evidence map›Paper›PMID 38915309›Full record

ArticleFrontiers in neuroscience2024

A clathrin mediated endocytosis scaffolding protein, Intersectin 1, changes in an isoform, brain region, and sex specific manner in Alzheimer's disease.

Sierra Jaye, Ursula S Sandau, Trevor J McFarland, Randy L Woltjer, Julie A Saugstad

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The Footprint ofCurrent Alzheimer research · 2025
    Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sierra JayeDepartment of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, OR, United States.
Ursula S SandauDepartment of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, OR, United States.
Trevor J McFarlandDepartment of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, OR, United States.
Randy L WoltjerDivision of Neuropathology, Department of Pathology, Oregon Health and Science University, Portland, OR, United States.
Julie A SaugstadDepartment of Anesthesiology and Perioperative Medicine, Oregon Health and Science University, Portland, OR, United States.

Funding

Research Education ComponentP30AG066518 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI Zachary Beattie · 2020 to 2026
$28.6M
Neuroscience of Aging, Neurodegeneration and Alzheimer’s DiseaseT32AG055378 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI JACOB RABER, HENRYK F URBANSKI · 2018 to 2026
$4.3M
Establishing MicroRNA Biomarkers for Diagnosing Alzheimer's Disease & Predicting ProgressionRF1AG059392 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI SAUGSTAD, JULIE ANNE · 2019 to 2019
$3.4M
NIA NIH HHS P30 AG066518NIA NIH HHS RF1 AG059392NIA NIH HHS T32 AG055378
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the most common form of dementia and is characterized by the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary Tau tangles in the brain. We previously identified a set of candidate AD microRNAs (miRNAs) in human cerebrospinal fluid (CSF) and used a target prediction pipeline to identify mRNAs and pathways that could potentially be regulated by the miRNAs. Of these pathways, clathrin mediated endocytosis (CME) was selected for further investigation. CME is altered in multiple brain cell types in AD and is implicated in early cellular phenotypes such as enlarged early endosomes and pathogenic processing of Aβ. However, a comprehensive evaluation of major CME hub proteins in humans with AD across multiple brain regions is lacking. Thus, we used immunoblots to evaluate human post-mortem AD and control (CTL) frontal cortex (FC; AD

Indexed as

5xFADAlzheimer’s diseaseclathrin mediated endocytosishuman brainIntersectin 1

Identifiers

PMID38915309
PMCPMC11195150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.